NASDAQ:PLRX

Pliant Therapeutics Q3 2026 Earnings Results & Report

Pliant Therapeutics logo
$0.69 0.00 (-0.55%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$0.69 0.00 (-0.03%)
As of 11/16/2026 05:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pliant Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.39 versus the -$0.3703 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
7:00 AM ET

Pliant Therapeutics EPS Results

Actual EPS
-$0.39
Consensus EPS
-$0.3703
Beat/Miss
Missed by -$0.0197
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Pliant Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pliant Therapeutics Q3 2026 Earnings FAQ

Pliant Therapeutics (NASDAQ:PLRX) reported earnings of -$0.39 per share for Q3 2026, missing the consensus estimate of -$0.3703. The report was announced on Thursday, November 12, 2026.

Pliant Therapeutics Earnings Headlines

Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
See More Pliant Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pliant Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pliant Therapeutics and other key companies, straight to your email.

About Pliant Therapeutics

Pliant Therapeutics (NASDAQ:PLRX) is a biopharmaceutical company focused on developing medicines for fibrotic diseases, in which excess scar tissue can impair the function of organs. The company’s research centers on integrins, proteins involved in processes such as tissue repair and fibrosis.

Its investigational programs have included bexotegrast, an oral drug designed to inhibit the αvβ6 and αvβ1 integrins and studied for conditions including idiopathic pulmonary fibrosis. Pliant has also pursued other drug candidates targeting fibrotic disease pathways. These medicines are investigational and are not approved treatments.

Based in South San Francisco, California, Pliant has conducted clinical research in the United States and other countries. Its work is focused on drug discovery and development rather than providing medical products or services directly to patients.

View Pliant Therapeutics Profile